Comparative Pharmacology
Head-to-head clinical analysis: MYDRIACYL versus PAREMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYDRIACYL versus PAREMYD.
MYDRIACYL vs PAREMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticholinergic agent that blocks muscarinic receptors in the eye, causing mydriasis and cycloplegia.
PAREMYD is a direct-acting vasodilator; its active metabolite, hydralazine, relaxes arteriolar smooth muscle by increasing cyclic guanosine monophosphate (cGMP) levels via inhibition of inositol trisphosphate (IP3) production, leading to reduced intracellular calcium and vasodilation.
For refraction: 1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated every 5-10 minutes for up to 3 doses; for cycloplegia: 1-2 drops of 1% solution topically, repeated once after 5 minutes.
10 mg orally twice daily; maximum daily dose: 20 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in adults; prolonged in elderly and patients with hepatic impairment
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 40 hours) necessitating dose adjustment.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 30%)
Primarily renal excretion of unchanged drug (60-80%) and hepatic metabolism (20-40%) with biliary-fecal elimination of metabolites.
Category C
Category C
Mydriatic
Mydriatic